Can Zetia (ezetimibe) be used in patients with myasthenia gravis? | Rounds Can Zetia (ezetimibe) be used in patients with myasthenia gravis? | Rounds
Loading...

Can Zetia (ezetimibe) be used in patients with myasthenia gravis?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: July 14, 2026 · View editorial policy

Ezetimibe Use in Myasthenia Gravis

Ezetimibe is not listed as a medication class with strong evidence for worsening myasthenia gravis (MG) in a widely used MG medication caution framework. [1] Published literature includes a case report of MG worsening in association with ezetimibe, which supports clinical monitoring after initiation or dose changes. [2]

Medication Safety Positioning

Ezetimibe is a cholesterol absorption inhibitor. [3] MG-specific guidance materials that review medication triggers for MG list cholesterol absorption inhibitors (including ezetimibe) as not evidenced to worsen MG. [4]

Practical Use Approach

Ezetimibe can be prescribed to patients with MG when clinically indicated for lipid management. [4] Worsening of MG symptoms should be monitored after starting ezetimibe or after any dose increase. [2]

Evidence Base Supporting This Use

A literature review and case report described a patient with MG who worsened while taking ezetimibe. [2] A recent MG medication consensus statement categorized ezetimibe (cholesterol absorption inhibitors) as having no evidence of worsening MG. [4]

Ezetimibe can be associated with muscle-related side effects such as muscle pain or weakness, which can mimic or mask MG symptom changes. [3]

Monitoring Considerations

Clinical monitoring for increased fatigability, ocular symptoms, bulbar symptoms, or respiratory compromise should occur after initiation and during ongoing therapy in MG patients. [2] If worsening occurs temporally after ezetimibe initiation or dose escalation, discontinuation and alternative lipid-lowering strategies should be considered in coordination with neurology/cardiology. [2]

Common Pitfalls to Avoid

Attributing new or worsening weakness solely to MG without evaluating medication timing and recent starts or dose changes can delay recognition of a drug-associated trigger. [2]

When to Seek Urgent Care

Any signs of myasthenic crisis, including respiratory compromise, should prompt urgent emergency evaluation. [5]

Related Questions